Resultats globals: 7 registres trobats en 0.02 segons.
Articles, 7 registres trobats
Articles 7 registres trobats  
1.
17 p, 921.2 KB Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes / Sauta, Elisabetta (Humanitas Clinical and Research Center (Itàlia)) ; Robin, Marie (Department of Hematology and Bone Marrow Transplantation. Hôpital Saint-Louis (França)) ; Bersanelli, Mateo (Department of Biomedical Sciences. Humanitas University) ; Travaglino, Erica (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ; Meggendorfer, Manje (Mll Munich Leukemia Laboratory) ; Zhao, Lin-Pierre (Department of Hematology and Bone Marrow Transplantation. Hôpital Saint-Louis (França)) ; Caballero Berrocal, Juan Carlos (Hematology Department. Hospital Universitario de Salamanca) ; Sala, Claudia (Experimental. Diagnostic and Specialty Medicine. Dimes) ; Maggioni, Giulia (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ; Bernardi, Massimo (University Vita-Salute San Raffaele (Itàlia)) ; Di Grazia, Carmen (Irccs Ospedale Policlinico San Martino) ; Vago, Luca (University Vita-Salute San Raffaele (Itàlia)) ; Rivoli, Giulia (Irccs Ospedale Policlinico San Martino) ; Borin, Lorenza (Ospedale San Gerardo) ; D'Amico, Saverio (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ; Tentori, Cristina Astrid (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ; Ubezio, Marta (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ; Campagna, Alessia (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ; Russo, Antonio (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ; Mannina, Daniele (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ; Lanino, Luca (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ; Chiusolo, Patrizia (Università Cattolica Del Sacro Cuore) ; Giaccone, Luisa (Department of Molecular Biotechnology and Health Sciences. University of Turin) ; Voso, Maria Teresa (Tor Vergata University) ; Riva, Maria (Asst Grande Ospedale Metropolitano Niguarda) ; Oliva, Esther Natalie (Grande Ospedale Metropolitano Bianchi Melacrino Morelli) ; Zampini, Matteo (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ; Riva, Elena (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ; Nibourel, Olivier (Chu Lille) ; Bicchieri, Marinela (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ; Bolli, Niccolo (Department of Oncology and Hemato-Oncology. University of Milan) ; Rambaldi, Alessandro (Azienda Ospedaliera Papa Giovanni Xxiii) ; Passamonti, Francesco (Department of Medicine and Surgery. University of Insubria) ; Savevski, Victor (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ; Santoro, Armando (Department of Biomedical Sciences. Humanitas University) ; Germing, Ulrich (Department of Hematology. Heinrich-Heine-University. University Clinic) ; Kordasti, Shahram (Hematology Department. DISCLIMO-Università Politecnica Delle Marche) ; Santini, Valeria (University of Florence) ; Diez-Campelo, María (Hospital Universitario de Salamanca) ; Sanz, Guillermo (Hospital Universitari i Politècnic La Fe (València)) ; Sole, F (Institut de Recerca Contra la Leucèmia Josep Carreras) ; Kern, Wolfgang (Mll Munich Leukemia Laboratory) ; Platzbecker, Uwe (University Hospital Leipzig) ; Arenillas, Leonor (Department of Hematology and Bone Marrow Transplantation. Hôpital Saint-Louis) ; Fenaux, Pierre (Department of Hematology and Bone Marrow Transplantation. Hôpital Saint-Louis) ; Haferlach, Torsten (Mll Munich Leukemia Laboratory) ; Castellani, Gastone (Experimental. Diagnostic and Specialty Medicine. Dimes) ; Della Porta, Matteo Giovanni (Department of Biomedical Sciences. Humanitas University)
PURPOSEMyelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms in which a risk-adapted treatment strategy is needed. Recently, a new clinical-molecular prognostic model, the Molecular International Prognostic Scoring System (IPSS-M) was proposed to improve the prediction of clinical outcome of the currently available tool (Revised International Prognostic Scoring System [IPSS-R]). [...]
2023 - 10.1200/JCO.22.01784
Journal of Clinical Oncology, Vol. 41 Núm. 15 (20 2023) , p. 2827-2842  
2.
4 p, 551.6 KB Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype / Mallo, Maria del Mar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Tuechler, Heinz (Boltzmann Institute for Leukaemia Research and Hematology) ; Arenillas, Leonor (Hospital del Mar (Barcelona, Catalunya)) ; Raynaud, Sophie (Cote d'Azur University) ; Cluzeau, Thomas (Cote d'Azur University) ; Shih, Lee-Yung (Chang Gung University) ; Tung-Liang, Chiang (Chang Gung University) ; Ganster, Christina (University Medical Center Göttingen) ; Shirneshan, Katayoon (University Medical Center Göttingen) ; Haase, Detlef (University Medical Center Göttingen) ; Mascaró, Martí (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ; Palomo Sanchís, Laura (Vall d'Hebron Institut d'Oncologia) ; Cervera, José (Hospital Universitari i Politècnic La Fe (València)) ; Such, Esperanza (Hospital Universitari i Politècnic La Fe (València)) ; Trim, Nicola (Birmingham Women's Hospital) ; Jeffries, Sally (Birmingham Women's Hospital) ; Ridgway, Emma (Birmingham Women's Hospital) ; Marconi, Giovanni (IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori") ; Martinelli, Giovanni (IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori") ; Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
Half of the myelodysplastic syndromes (MDS) have normal karyotype by conventional banding analysis. The percentage of true normal karyotype cases can be reduced by 20-30% with the complementary application of genomic microarrays. [...]
2023 - 10.1002/jha2.651
EJHaem, Vol. 4 (february 2023) , p. 446-449  
3.
13 p, 3.0 MB Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q / Ademà, Vera (Department of Translational Hematology and Oncology Research. Lerner Research Institute. Cleveland Clinic. Taussig Cancer Institute) ; Palomo Sanchís, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Walter, Wencke (Munich Leukemia Laboratory) ; Mallo, Maria del Mar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Hutter, Stephan (Munich Leukemia Laboratory) ; La Framboise, Thomas (Department of Genetics and Genome Sciences. Case Western Reserve University) ; Arenillas, Leonor (Institut Hospital del Mar d'Investigacions Mèdiques) ; Meggendorfer, Manja (Munich Leukemia Laboratory) ; Radivoyevitch, Tomas (Department of Translational Hematology and Oncology Research. Lerner Research Institute. Cleveland Clinic. Taussig Cancer Institute) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Pellagatti, Andrea (Blood Cancer UK Molecular Haematology Unit. Nuffield Division of Clinical Laboratory Sciences. Radcliffe Department of Medicine. University of Oxford and Oxford BRC Haematology Theme) ; Haferlach, Claudia (Munich Leukemia Laboratory) ; Boultwood, Jacqueline (University of Oxford. Radcliffe Department of Medicine) ; Kern, Wolfgang (Munich Leukemia Laboratory) ; Visconte, Valeria (Department of Translational Hematology and Oncology Research. Lerner Research Institute. Cleveland Clinic. Taussig Cancer Institute) ; Sekeres, Mikkael (Leukemia Program. Department of Hematology and Medical Oncology. Cleveland Clinic. Cleveland Clinic Taussig Cancer Institute) ; Barnard, John (Department of Quantitative Health Sciences. Cleveland Clinic. Lerner Research Institute) ; Haferlach, Torsten (Munich Leukemia Laboratory) ; Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Maciejewski, Jaroslaw (Department of Translational Hematology and Oncology Research. Lerner Research Institute. Cleveland Clinic. Taussig Cancer Institute)
Background: Haploinsufficiency (HI) resulting from deletion of the long arm of chromosome 5 [del(5q)] and the accompanied loss of heterozygosity are likely key pathogenic factors in del(5q) myeloid neoplasia (MN) although the consequences of del(5q) have not been yet clarified. [...]
2022 - 10.1016/j.ebiom.2022.104059
EBioMedicine, Vol. 80 (june 2022) , art. 104059  
4.
11 p, 1.9 MB Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma / Recasens-Zorzo, Clara (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Cardesa-Salzmann, Teresa (Hospital Clínic i Provincial de Barcelona) ; Petazzi, Paolo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Ros-Blanco, Laia (Universitat Ramon Llull. Institut Químic de Sarrià-IQS) ; Esteve-Arenys, Anna (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Clot, Guillem (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Guerrero-Hernández, Martina (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Rodríguez, Vanina (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Soldini, Davide (Hospital Clínic i Provincial de Barcelona) ; Valera, Alexandra (Hospital Clínic i Provincial de Barcelona) ; Moros, Alexandra (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Climent, Fina (Hospital Universitari de Bellvitge) ; Gonzalez-Barca, Eva (Institut Català d'Oncologia) ; Mercadal, Santiago (Institut Català d'Oncologia) ; Arenillas, Leonor (Institut Hospital del Mar d'Investigacions Mèdiques) ; Calvo, Xavier (Institut Hospital del Mar d'Investigacions Mèdiques) ; Mate Sanz, Jose Luís (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Gutiérrez-García, Gonzalo (Hospital Clínic i Provincial de Barcelona) ; Casanova Rigat, Isolda (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Mangues, Ramon 1957- (Institut d'Investigació Biomèdica Sant Pau) ; Sanjuan-Pla, Alejandra (Hospital Universitari i Politècnic La Fe (València)) ; Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Martínez, Antonio (Hospital Clínic i Provincial de Barcelona) ; Colomer, Dolors (Hospital Clínic i Provincial de Barcelona) ; Estrada Tejedor, Roger (Universitat Ramon Llull) ; Teixidó, Jordi (Universitat Ramon Llull) ; Campo, Elias (Hospital Clínic i Provincial de Barcelona) ; López-Guillermo, A. (Hospital Clínic i Provincial de Barcelona) ; Borrell, José Ignacio (Universitat Ramon Llull) ; Colomo, Luis (Institut Hospital del Mar d'Investigacions Mèdiques) ; Pérez-Galán, Patricia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Roué, Gaël (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
Constitutive activation of the chemokine receptor CXCR4 has been associated with tumor progression, invasion, and chemotherapy resistance in different cancer subtypes. Although the CXCR4 pathway has recently been suggested as an adverse prognostic marker in diffuse large B-cell lymphoma, its biological relevance in this disease remains underexplored. [...]
2019 - 10.3324/haematol.2017.180505
Haematologica, Vol. 104 Núm. 4 (31 2019) , p. 778-788  
5.
14 p, 3.0 MB Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival / Cabezón, Marta (Universitat Autònoma de Barcelona. Departament de Medicina) ; Malinverni, Roberto (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Bargay, Joan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Marcé, Silvia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Garrido, Ana (Institut d'Investigació Biomèdica Sant Pau) ; Tormo, M. (Hospital Clínic Universitari (València)) ; Arenillas, Leonor (Hospital del Mar (Barcelona, Catalunya)) ; Coll, Rosa (Hospital Universitari de Girona Doctor Josep Trueta) ; Borrás, Josep (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ; Jiménez, María José (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Hoyos Colell, Montserrat (Institut d'Investigació Biomèdica Sant Pau) ; Valcárcel, David (Hospital Universitari Vall d'Hebron) ; Escoda, Lourdes (Hospital Universitari Joan XXIII de Tarragona) ; Vall-Llovera, Ferran (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ; Garcia, A. (Hospital Arnau de Vilanova (Lleida, Catalunya)) ; Font, L. L. (Hospital de Tortosa Verge de la Cinta) ; Ramila, Elena (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Buschbeck, Marcus (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Zamora, Lurdes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Epigenetic therapy, using hypomethylating agents (HMA), is known to be effective in the treatment of high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) patients who are not suitable for intensive chemotherapy and/or allogeneic stem cell transplantation. [...]
2021 - 10.1186/s13148-021-01002-y
Clinical Epigenetics, Vol. 13 (january 2021)  
6.
6 p, 408.9 KB Prognostic impact of circulating plasma cells in patients with multiple myeloma : implications for plasma cell leukemia definition / Granell, Miquel (Institut d'Investigació Biomèdica Sant Pau) ; Calvo, Xavier (Institut Hospital del Mar d'Investigacions Mèdiques) ; Garcia-Guiñón, Antoni (Hospital Arnau de Vilanova (Lleida, Catalunya)) ; Escoda, Lourdes (Hospital Universitari Joan XXIII de Tarragona) ; Abella Monreal, Eugenia (Institut Hospital del Mar d'Investigacions Mèdiques) ; Martínez, Clara Mª (Institut d'Investigació Biomèdica Sant Pau) ; Teixidó, Montserrat (Hospital Arnau de Vilanova (Lleida, Catalunya)) ; Gimenez, Mª Teresa (Hospital Universitari Joan XXIII de Tarragona) ; Senín, Alicia (Institut Hospital del Mar d'Investigacions Mèdiques) ; Sanz, Patricia (Institut d'Investigació Biomèdica Sant Pau) ; Campoy, Desirée (Hospital Arnau de Vilanova (Lleida, Catalunya)) ; Vicent, Ana (Hospital Universitari Joan XXIII de Tarragona) ; Arenillas, Leonor (Institut Hospital del Mar d'Investigacions Mèdiques) ; Rosiñol, Laura (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ; Bladé Creixenti, Juan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Fernandez de Larrea Rodriguez, Carlos (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Universitat Autònoma de Barcelona
The presence of circulating plasma cells in patients with multiple myeloma is considered a marker for highly proliferative disease. In the study herein, the impact of circulating plasma cells assessed by cytology on survival of patients with multiple myeloma was analyzed. [...]
2017 - 10.3324/haematol.2016.158303
Haematologica, Vol. 102 (june 2017) , p. 1099-1104  
7.
7 p, 184.9 KB Trisomy 8, a cytogenetic abnormality in Myelodysplastic Syndromes, is constitutional or not? / Saumell i Tutusaus, Sílvia (Universitat Autònoma de Barcelona. Departament de Medicina) ; Solé Ristol, Francesc (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Arenillas, Leonor (Hospital del Mar (Barcelona, Catalunya)) ; Montoro Gómez, Julia (Hospital Universitari Vall d'Hebron) ; Valcarcel Ferreiras, David (Hospital Universitari Vall d'Hebron) ; Pedro, Carme (Institut Hospital del Mar d'Investigacions Mèdiques) ; Sanzo, Carmen (Hospital Universitario Central de Asturias) ; Luño, Elisa (Hospital Universitario Central de Asturias) ; Giménez, Teresa (Hospital Universitari Joan XXIII de Tarragona) ; Arnan, Montserrat (Institut Català d'Oncologia) ; Pomares, Helena (Institut Català d'Oncologia) ; De Paz, Raquel (Hospital Universitario La Paz (Madrid)) ; Arrizabalaga, Beatriz (Hospital Universitario de Cruces (Barakaldo, País Basc)) ; Jerez, Andrés (Hospital General Universitario Morales Meseguer (Múrcia)) ; Martínez, Ana B. (Hospital General Universitario Morales Meseguer (Múrcia)) ; Sánchez-Castro, Judith (Hospital Arnau de Vilanova (Lleida, Catalunya)) ; Rodríguez-Gambarte, Juan D. (Hospital Universitario Ramón y Cajal (Madrid)) ; Raya, José M. (Hospital Universitario de Canarias (La Laguna)) ; Ríos, Eduardo (Hospital Universitario Virgen de Valme (Sevilla, Andalusia)) ; Rodríguez-Rivera, María (Hospital del Mar (Barcelona, Catalunya)) ; Espinet i Solà, Blanca (Hospital del Mar (Barcelona, Catalunya)) ; Florensa, L. (Hospital del Mar (Barcelona, Catalunya))
Isolated trisomy 8 is not considered presumptive evidence of myelodysplastic syndrome (MDS) in cases without minimal morphological criteria. One reason given is that trisomy 8 (+8) can be found as a constitutional mosaicism (cT8M). [...]
2015 - 10.1371/journal.pone.0129375
PloS one, Vol. 10, No 6 (June 2015) , p. e0129375  

Vegeu també: autors amb noms similars
8 Arenillas, Leonor
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.